RU2661407C2 - Вакцинная композиция для неиммунизированных индивидуумов - Google Patents

Вакцинная композиция для неиммунизированных индивидуумов Download PDF

Info

Publication number
RU2661407C2
RU2661407C2 RU2015129028A RU2015129028A RU2661407C2 RU 2661407 C2 RU2661407 C2 RU 2661407C2 RU 2015129028 A RU2015129028 A RU 2015129028A RU 2015129028 A RU2015129028 A RU 2015129028A RU 2661407 C2 RU2661407 C2 RU 2661407C2
Authority
RU
Russia
Prior art keywords
acid
virus
vaccine
influenza
use according
Prior art date
Application number
RU2015129028A
Other languages
English (en)
Russian (ru)
Other versions
RU2015129028A (ru
Inventor
Ханс АРВИДССОН
Анна-Карин МАЛЬТАИС
Original Assignee
Юросайн Вэксинз Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юросайн Вэксинз Аб filed Critical Юросайн Вэксинз Аб
Publication of RU2015129028A publication Critical patent/RU2015129028A/ru
Application granted granted Critical
Publication of RU2661407C2 publication Critical patent/RU2661407C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
RU2015129028A 2012-12-17 2013-12-17 Вакцинная композиция для неиммунизированных индивидуумов RU2661407C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12197522.1A EP2742952A1 (en) 2012-12-17 2012-12-17 Influenza vaccine composition
EP12197522.1 2012-12-17
PCT/EP2013/077006 WO2014095943A1 (en) 2012-12-17 2013-12-17 Vaccine composition for naive subjects

Publications (2)

Publication Number Publication Date
RU2015129028A RU2015129028A (ru) 2017-01-23
RU2661407C2 true RU2661407C2 (ru) 2018-07-16

Family

ID=47358019

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2015129028A RU2661407C2 (ru) 2012-12-17 2013-12-17 Вакцинная композиция для неиммунизированных индивидуумов
RU2015129077A RU2661408C2 (ru) 2012-12-17 2013-12-17 Вакцинная композиция для применения в популяциях субъектов с ослабленным иммунитетом

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015129077A RU2661408C2 (ru) 2012-12-17 2013-12-17 Вакцинная композиция для применения в популяциях субъектов с ослабленным иммунитетом

Country Status (12)

Country Link
US (2) US11065325B2 (enExample)
EP (4) EP2742952A1 (enExample)
JP (3) JP2016502996A (enExample)
KR (3) KR20210007042A (enExample)
CN (3) CN104884085A (enExample)
AU (2) AU2013360889C1 (enExample)
BR (2) BR112015014243A8 (enExample)
CA (2) CA2895023A1 (enExample)
HK (2) HK1212611A1 (enExample)
MX (2) MX2015007753A (enExample)
RU (2) RU2661407C2 (enExample)
WO (2) WO2014095944A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130243817A1 (en) * 2010-09-30 2013-09-19 Eurocine Vaccines Ab Vaccine compositions
ES2927797T3 (es) * 2014-09-26 2022-11-11 Seqirus Uk Ltd Vacunación de sujetos inmunocomprometidos
JP2017528511A (ja) 2014-09-26 2017-09-28 セキラス ユーケー リミテッド 免疫低下された被験体のワクチン接種
RU2634247C2 (ru) * 2015-09-28 2017-10-24 Федеральное государственное бюджетное научное учреждение "СЕВЕРО-КАВКАЗСКИЙ ЗОНАЛЬНЫЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ВЕТЕРИНАРНЫЙ ИНСТИТУТ" (ФГБНУ СКЗНИВИ) Способ стимуляции иммунного ответа и препарат для его осуществления
WO2019108928A1 (en) * 2017-11-30 2019-06-06 Ohio State Innovation Foundation Mucoadhesive nanoparticle entrapped influenza virus vaccine delivery system
BR112022020792A2 (pt) * 2020-04-16 2022-11-29 Bayer Ag Combinações de compostos ativos e composições fungicidas compreendendo-as
LT4135519T (lt) * 2020-04-16 2024-12-27 Bayer Aktiengesellschaft Veikliųjų medžiagų deriniai ir juos apimančios fungicidų kompozicijos
WO2021209364A1 (en) * 2020-04-16 2021-10-21 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
CN112063699B (zh) * 2020-09-16 2021-06-18 成都市疾病预防控制中心 一种用于研究hiv感染者免疫衰老机制的系统
EP4463180A4 (en) * 2022-01-10 2026-06-17 Childrens Medical Ct Corp METHODS AND COMPOSITIONS RELATING TO THE IMMUNIZATION OF DISTINCTIVE IMMUNE PATIENTS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2390351C2 (ru) * 2003-08-11 2010-05-27 Дзе Ресерч Фаундейшн Фо Макробайал Дизизес Оф Осака Юниверсити Вакцина против вируса гриппа для введения через слизистую и способ предотвращения гриппа
US20100260797A1 (en) * 2007-12-06 2010-10-14 Emmanuel Jules Hanon Influenza composition
WO2012042003A1 (en) * 2010-09-30 2012-04-05 Eurocine Vaccines Ab Improved vaccine compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9602280D0 (sv) 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
SE9900496D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
ES2399386T3 (es) 2001-04-05 2013-04-01 Novartis Vaccines And Diagnostics, Inc. Aumento de la inmunidad de las mucosas tras sensibilización parenteral
US20050208602A1 (en) 2001-08-10 2005-09-22 Rosen Craig A 89 human secreted proteins
AU2003301843A1 (en) 2002-05-17 2004-06-07 Human Genome Sciences, Inc. 157 human secreted proteins
ES2352671T3 (es) 2002-11-26 2011-02-22 Eurocine Vaccines Ab Nuevo adyuvante a base de amina.
US7964200B2 (en) 2005-05-18 2011-06-21 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against Chlamydia infection
EP2292628A3 (en) 2005-06-30 2011-05-11 Eisai R&D Management Co., Ltd. Compounds for preparing immunological adjuvant
EP1930025B1 (en) 2005-08-05 2013-05-01 The University of Tokushima ANTIGEN-AND-DRUG VEHICLE WHICH ENABLES THE CHANGEOVER FROM THE SELECTIVE PRODUCTION OF IgA ANTIBODY TO THE PRODUCTION OF BOTH OF IgA AND IgG ANTIBODIES, AND TRANSNASAL/TRANSMUCOSAL VACCINE USING THE VEHICLE
RU2323742C1 (ru) * 2007-02-15 2008-05-10 Государственное учреждение Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова (ГУ НИИВС им. И.И. Мечникова) Способ повышения иммуногенности инактивированной гриппозной вакцины
EP2293814A4 (en) 2008-05-23 2013-02-13 Univ Michigan NANOEMULSION AGENTS
US8877208B2 (en) 2008-05-23 2014-11-04 The Regents Of The University Of Michigan Multivalent nanoemulsion vaccines
US20130178383A1 (en) 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
KR101704988B1 (ko) 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2390351C2 (ru) * 2003-08-11 2010-05-27 Дзе Ресерч Фаундейшн Фо Макробайал Дизизес Оф Осака Юниверсити Вакцина против вируса гриппа для введения через слизистую и способ предотвращения гриппа
US20100260797A1 (en) * 2007-12-06 2010-10-14 Emmanuel Jules Hanon Influenza composition
WO2012042003A1 (en) * 2010-09-30 2012-04-05 Eurocine Vaccines Ab Improved vaccine compositions

Also Published As

Publication number Publication date
EP2931308A1 (en) 2015-10-21
CA2895023A1 (en) 2014-06-26
KR20210007042A (ko) 2021-01-19
EP2931307B1 (en) 2018-09-12
BR112015014174A2 (pt) 2017-07-11
WO2014095943A1 (en) 2014-06-26
HK1212611A1 (zh) 2016-06-17
RU2015129028A (ru) 2017-01-23
RU2015129077A (ru) 2017-01-23
KR20150132093A (ko) 2015-11-25
JP2019112448A (ja) 2019-07-11
EP3431101A1 (en) 2019-01-23
US20150306204A1 (en) 2015-10-29
HK1213492A1 (zh) 2016-07-08
JP2016502997A (ja) 2016-02-01
MX2015007688A (es) 2015-09-07
CN104884085A (zh) 2015-09-02
RU2661408C2 (ru) 2018-07-16
EP2742952A1 (en) 2014-06-18
EP2931308B1 (en) 2018-10-10
US11065325B2 (en) 2021-07-20
KR20150132092A (ko) 2015-11-25
CN112826929A (zh) 2021-05-25
AU2013360889B2 (en) 2016-12-01
AU2013360890A1 (en) 2015-07-02
BR112015014243A8 (pt) 2019-10-08
AU2013360889C1 (en) 2017-06-08
CA2895028A1 (en) 2014-06-26
EP2931307A1 (en) 2015-10-21
US20150306205A1 (en) 2015-10-29
CN104870010A (zh) 2015-08-26
JP2016502996A (ja) 2016-02-01
MX2015007753A (es) 2016-01-08
WO2014095944A1 (en) 2014-06-26
BR112015014243A2 (pt) 2017-07-11
AU2013360889A1 (en) 2015-07-02
AU2013360890B2 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
EP2931307B1 (en) Influenza vaccine composition for naive subjects
JP5809560B2 (ja) インフルエンザに対して使用するためのワクチン組成物
JP6839088B2 (ja) 手足口病ワクチン、ならびにその製造方法及び使用方法
JP2016516755A (ja) ワクチン組成物及びその使用方法
JP2009209086A (ja) 粘膜投与型ワクチン
Fonseca et al. Immunological profile of mice immunized with a polyvalent virosome-based influenza vaccine
CN104582726A (zh) 狂犬病病毒免疫原的含佐剂制剂
US8535683B2 (en) Intranasal or inhalational administration of virosomes
Nurpeisova et al. Analysis of the efficacy of an adjuvant-based inactivated pandemic H5N1 influenza virus vaccine: A. Nurpeisova et al.
AU2007228736B2 (en) Intranasal influenza vaccine based on virosomes
US20080038294A1 (en) Intranasal or inhalational administration of virosomes
CN101405027B (zh) 基于病毒颗粒的鼻内流感疫苗
Willis The Effect of Maternal Antibodies on Anti-viral Immunity in Infant Mice
WO2024232415A1 (ja) インフルエンザ及びコロナウイルス感染症予防のための混合ワクチン

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20191218